Menopause Treatment Access, Forever Chemicals and Breast Cancer Risk, and New Vaccines for the Ebola Outbreak
Trial status and details compiled from ClinicalTrials.gov. Results and topline data drawn from sponsor releases or publications, where applicable. Regulatory information drawn from the FDA. Research accurate as of November 9, 2026.
The FDA has approved updated labeling on boxed warnings for three menopausal hormone therapy products and is exploring the possibility of vaginal estrogen being sold over-the-counter to address access challenges. In oncology, an NIH analysis has found associations between two widely used industrial chemicals and estrogen-receptor-negative breast cancer, and phase 3 results from the INTerpath-001 trial were presented at the 2026 ESMO Congress, showing that a personalized mRNA-based therapy may reduce the risk of melanoma recurrence when combined with pembrolizumab. In global health, the WHO has recommended that two vaccine candidates be added to the TUMAINI trial in response to the Ebola disease outbreak in the DRC.
FDA Explores Over-the-Counter Vaginal Estrogen and Updates Menopause Therapy Labels
Since the announcement last year, November 2025, from the U.S. Department of Health and Human Services (HHS) that the FDA would be updating the black box warning on menopausal HRT products, there have been approved updated labelings for a total of nine products. The label changes include the removal of certain statements relating to the risk of heart disease, breast cancer, and dementia. According to the FDA, these changes are a reflection of the most current available scientific literature and information on the benefit-risk profile of these treatments. The agency approved labeling changes for the first six menopausal hormone therapy products earlier this year in February 2026 and a further three products (all estradiol transdermal patches) last month on the 30th of October.
Although the FDA has stated that they are not currently aware of an imminent risk of a nationwide shortage, the agency recognizes that the label updates may have contributed to a rise in demand and is currently engaging with the manufacturers of FDA-approved estradiol transdermal patches to expand production. To further address any access challenges, last month, on the 20th October, the FDA approved a generic version of the once-weekly Climara Pro transdermal hormone therapy patch. This patch contains both estrogen and progestogen and is approved for women who still have their uterus, for the treatment of moderate to severe menopause symptoms or for the prevention of postmenopausal osteoporosis. This generic version could help to make treatment more accessible for more patients.
In a further development (one that could potentially make vaginal estrogen therapy more accessible for patients) the FDA said that it is working together with sponsors to explore the possibility of moving certain vaginal estrogen products to over-the-counter (OTC) status. Low-dose vaginal estrogen can be an effective treatment for moderate to severe genitourinary syndrome of menopause (GSM), which can include symptoms like vaginal dryness, discomfort during sex, and repeated urinary tract infections. Currently, vaginal estrogen products in the U.S. need a prescription and are not available over-the-counter. Any transition to OTC would require separate FDA approval, and the transition would need to be backed by evidence showing that consumers are able to appropriately select and use the products in a safe and effective way without being supervised by a healthcare provider.
NIH Study Finds Link Between PFAS Exposure and ER-Negative Breast Cancer
PFAS (perfluoroalkyl and polyfluoroalkyl substances) are a group of synthetic chemicals that are used in many industries, including the consumer, manufacturing, and healthcare sectors. Exposure can be through PFAS-contaminated water or food, using consumer products that contain PFAS, such as certain non-stick cookware or food packaging, or breathing in contaminated air. PFAS do not degrade (break down) easily and are sometimes called ‘forever chemicals’ because of their persistence in the environment. With repeated exposure, blood levels of these chemicals may build up within the body, and there are potential concerns about how these chemicals might be linked to adverse health effects, including increased risks of certain cancers and effects on metabolism and the immune system.
The National Institutes of Health (NIH) reported on the 5th November 2026 that a new study showed an association between higher blood levels of two PFAS and an increased incidence of estrogen receptor-negative breast cancer in women. This is a type of breast cancer that does not have receptors for the hormone estrogen, so certain hormone-blocking therapies may not be effective for this type of cancer. The findings of this study were published in the Journal of Clinical Oncology.
The analysis used the Sister Study, which is a prospective cohort study of 50,884 women who did not have breast cancer when joining the study, but each had a full- or half-sister with (or previously diagnosed with) breast cancer. The PFAS study included 1609 of these women who then went on to develop breast cancer, as well as a comparison sample of 2269 women. Blood was collected years prior to a cancer diagnosis and used to measure levels of 17 different PFAS.
Women with the highest blood levels of a type of PFAS called perfluoro-n-octanoic acid (PFOA) had a 67% higher rate of estrogen-receptor-negative breast cancer compared to women in the lowest level of exposure group. Similarly, women with the highest blood levels of perfluorooctane-1-sulfonic acid (PFOS) had a 93% higher rate of estrogen-receptor-negative breast cancer compared to women in the lowest level of exposure group. Importantly, there were no clear associations found between these two PFAS and estrogen-receptor-positive breast cancer or breast cancer risk overall. The researchers then went on to further support the association between PFOA and ER-negative breast cancer with a meta-analysis of prior studies, but the evidence for PFOS was less conclusive. This study is observational, which means that although it found an association between PFAS and estrogen receptor-negative breast cancer, it cannot establish that PFAS exposure causes it.
PFAS are often discussed as endocrine disruptors (which interfere with hormone systems), but in this study the association was with a cancer type that does not have hormone receptors. The authors of the study suggest that PFAS might operate through nonhormonal mechanisms like epigenetic alterations (which change how genes are expressed) or suppressing the immune system, but these mechanisms were not directly investigated in this study. More research is necessary to investigate the effects of high PFAS exposure, as well as the effects of newer PFAS chemicals.
Personalized mRNA Therapy Shows Positive Phase 3 Results in Melanoma
Melanoma is a type of skin cancer that begins in melanocytes, which are the cells that make the pigment melanin. For some people with resectable melanoma (melanoma that may be completely removed with surgery), there is still a high risk of the cancer returning despite the surgical removal or adjuvant treatment with immunotherapy such as pembrolizumab. Adding an individualized mRNA-based neoantigen therapy (intismeran autogene) in combination with pembrolizumab may help to reduce this risk of recurrence, according to results from a phase 3 trial called INTerpath-001.
Intismeran is an investigational mRNA therapy that is personalized to each patient according to a sample of their tumour, using the individual patient’s genetic mutations. The therapy then aims to direct the patient’s immune system towards the specific neoantigens (new proteins that are produced by cancer cells).
Results from an interim analysis of INTerpath-001 were presented last month at the 2026 ESMO Congress (a global oncology meeting) on the 24th October. The trial included 1137 adults with completely resected stage II to IV melanoma, who then received either intismeran in combination with pembrolizumab or placebo with pembrolizumab. After a median follow-up of 24.6 months, the combination of intismeran and pembrolizumab reduced the risk of the cancer returning (or death) by 42% compared to placebo and pembrolizumab alone (hazard ratio 0.58). 82.2% of patients who were treated with the combination therapy were alive and free of recurrence at the 24-month mark, compared to 70% for those treated with placebo and pembrolizumab only. This analysis did not show any overall survival benefit; however, this could possibly reflect the short follow-up duration, and the trial is still ongoing.
Trial record: NCT05933577
Two Vaccine Candidates For Bundibugyo Virus to Join TUMAINI Clinical Trial in Ebola Outbreak
The Centers for Disease Control and Prevention (CDC) is currently mobilizing resources and coordinating containment efforts in response to the Ebola disease outbreak in the Democratic Republic of the Congo (DRC).
Ebola disease is caused by a group of viruses called Orthoebolavirus, and there are six species that have been identified. The three that are responsible for outbreaks are the Ebola virus, the Sudan virus, and the Bundibugyo virus. The current Ebola disease outbreak is caused by the Bundibugyo virus and so far (accurate as of 6th November 2026), it has resulted in 10910 confirmed cases and 5306 total confirmed deaths. There is currently no approved vaccine or treatment for the Bundibugyo virus, only for the Ebola virus, but they are currently under development.
The TUMAINI trial was launched on the 23rd of October 2026, and it is a phase 2/3 randomized controlled platform trial that is investigating vaccines against the Bundibugyo virus in contacts of confirmed Bundibugyo virus disease cases, and it is designed so that multiple vaccines can be evaluated within the trial. Ervebo (which is a vaccine that is FDA-approved for the prevention of disease caused by Zaire ebolavirus) is the first vaccine to be evaluated in the trial to see whether it also offers protection against Bundibugyo virus.
On the 4th of November 2026, the WHO announced that two additional vaccine candidates had been recommended for evaluation in the ongoing TUMAINI trial, based on preclinical as well as early clinical evidence. The WHO expects that results from the TUMAINI trial will be available in early 2027.
Trial record: NCT07842107
Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. Consult a qualified healthcare professional regarding specific health questions.